MelissaInformatics Named Winner of CIO's Review's Award for 20 most promosing Data Integration Solutions Providers

Life Science/Healthcare Industry Leader Chosen by Panel Made Up of Experts and CIO Review Editorial Team.

Berkeley, CA / Montreal, Canada - March 14, 2016

IO Informatics (IOI - www.io-informatics.com) has been chosen to receive CIO Review's Award for "20 Most Promising Data Integration Solution Providers of 2015."

The selection panel, made up of domain experts and members of the CIO Review Editorial Team (www.cioreview.com), analyzed over 300 companies that provide Data Integration Solutions. The review panel then chose the top 20 companies that are at the forefront of tackling customer challenges.

"We are delighted and honoured to receive this award from CIO Review," said Robert Stanley, CEO and Founder of IO Informatics, Inc. "This reflects innovative yet mature development and services by a very dedicated IOI team, as well longterm engagement and priceless feedback from our customers and partners."

"From IOI's inception, our goal has been to accelerate healthcare and life science innovation by improving access to meaningful data and resources required for knowledge creation and insight. We meet this goal by providing the most agile enterprise scale solutions to the toughest data harmonization, integration, search and reasoning challenges associated with the growth of Big Data and Precision Medicine. By harnessing and incorporating the latest advances in Linked Data and computer-based reasoning, anyone who calls on IOI's software and services are able to more efficiently integrate, deeply search and most importantly to harvest knowledge from data related to an area of interest. This gives our customers a substantially higher return on historical and new data and technology investments."

IOI provides software and services for data integration, knowledge engineering, and end-user searching and reporting interfaces utilizing its Sentient SuiteT of applications. We work primarily with customers in disease research foundations, biotechnology and pharmaceutical firms, academic centers of excellence, government bodies, and hospitals.